MedTrace Logo

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-10-01

No results posted yet for this study

Summary

A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumors
  • MET Gene Alterations

Interventions

DRUG

elzovantinib (TPX-0022)

Oral elzovantinib (TPX-0022) capsules

Sponsors & Collaborators

  • Turning Point Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2024-01-08
Completion
2027-03-03
FDA Drug
Yes

Countries

  • United States
  • France
  • North Korea
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03993873 on ClinicalTrials.gov